Litigation Details for AbbVie Inc. v. Hetero USA Inc. (D. Del. 2013)

AbbVie Inc. v. Hetero USA Inc. (D. Del. 2013)

Docket		Date Filed	2013-05-15
Court	District Court, D. Delaware	Date Terminated	2014-11-18
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,037,157; 6,703,403; 7,148,359; 7,364,752; 8,268,349; 8,691,878
Link to Docket	External link to docket

Details for AbbVie Inc. v. Hetero USA Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-05-15				External link to document

AbbVie Inc. v. Hetero USA Inc., 1:13-cv-00852: Litigation Summary and Patent Analysis

Last updated: August 13, 2026

AbbVie Inc. v. Hetero USA Inc., No. 1:13-cv-00852, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Hetero’s proposed generic version of AndroGel 1.62%, AbbVie’s testosterone replacement gel. AbbVie sued after receiving Hetero’s Paragraph IV certification. The case ended without a reported trial judgment, claim-construction ruling, or invalidity decision. The public docket reflects resolution and dismissal rather than adjudication on the merits. The dispute centered on U.S. Patent No. 6,503,894, which covered testosterone gel compositions and methods of use associated with AndroGel products.[1][2]

What drug and ANDA were involved in AbbVie v. Hetero?

The case concerned a proposed generic testosterone gel equivalent to AndroGel 1.62%.

Field	Details
Brand drug	AndroGel 1.62%
Active ingredient	Testosterone
Dosage form	Topical transdermal gel
Therapeutic category	Androgen replacement therapy
Brand owner at litigation	AbbVie Inc.
Generic applicant	Hetero USA Inc., associated with Hetero Labs
Court	U.S. District Court for the District of Delaware
Case number	1:13-cv-00852
Filing year	2013
Legal pathway	Hatch-Waxman ANDA litigation
Primary patent identified in the case record	U.S. Patent No. 6,503,894
Outcome	Resolved and dismissed without a reported merits judgment

AndroGel 1.62% was approved by the FDA in 2011. The product delivers testosterone through the skin and was approved for replacement therapy in men with conditions associated with a deficiency or absence of endogenous testosterone.[3]

What patents protected AndroGel 1.62% in the Hetero litigation?

The principal patent associated with the Hetero litigation was U.S. Patent No. 6,503,894, titled “Androgenic compositions and methods of use.” The patent covered testosterone gel compositions and related administration methods.

Patent	Subject matter	Filing and priority profile	Listed expiration
U.S. 6,503,894	Testosterone gel compositions and methods of use	Filed in the early 2000s; priority associated with the AndroGel development program	August 2020, subject to any applicable patent-term adjustment or extension

The Orange Book identified Patent No. 6,503,894 in connection with AndroGel products during the relevant period.[3] The scope of the patent was commercially important because a Paragraph IV challenge to the listed patent could create an immediate infringement action and a statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

The case should not be read as establishing that every AndroGel formulation patent was litigated against Hetero. Later AndroGel products and generic applications involved additional patents, patent-listing issues, and separate defendants. Patent coverage depended on the particular strength, formulation, labeling, and ANDA at issue.

What Paragraph IV challenge triggered the lawsuit?

Hetero’s ANDA included a Paragraph IV certification asserting that the relevant AbbVie patent was invalid, unenforceable, or would not be infringed by Hetero’s proposed product. AbbVie responded by filing suit within the statutory 45-day period.

The Paragraph IV filing had three direct consequences:

1. It created an artificial act of infringement under 35 U.S.C. § 271(e)(2).
2. It triggered the FDA’s potential 30-month approval stay.
3. It shifted the commercial dispute to federal court before generic approval.

The public case record does not show a final opinion determining whether Hetero’s product infringed the asserted claims or whether the patent was valid. There was no reported Markman decision, summary-judgment ruling, or trial verdict in the action.

When did AbbVie v. Hetero end?

The case ended through resolution followed by dismissal. The public docket does not provide a merits judgment against Hetero. The dismissal indicates that the parties reached a negotiated resolution or otherwise eliminated the need for continued litigation.

Procedural issue	Status
Complaint filed	2013
Answer and patent defenses	Filed during the action
Claim construction	No reported dispositive construction
Infringement trial	None reported
Invalidity trial	None reported
Final merits judgment	None reported
Settlement or negotiated resolution	Reflected by case termination and dismissal
Case status	Closed

The dismissal does not establish that Patent No. 6,503,894 was valid, infringed, or enforceable. It also does not establish that Hetero’s proposed generic would have been blocked until patent expiration. Those questions remained unresolved in the public record.

What was the settlement agreement and generic entry date?

The parties’ complete settlement terms were not disclosed in the reported court decisions. Public docket materials for the case do not provide a judicial finding that fixes Hetero’s launch date or describes the full economic terms of the agreement.

As a result, the case does not support a definitive public conclusion on:

• Hetero’s agreed generic launch date;
• whether Hetero received a license before patent expiration;
• whether AbbVie provided a business arrangement or supply agreement;
• whether the settlement contained restrictions tied to other testosterone products;
• whether the Federal Trade Commission reviewed or challenged the agreement.

The absence of a merits judgment is commercially significant. A settlement can preserve the brand company’s market position while avoiding the cost and risk of patent invalidity litigation. For the generic applicant, a settlement can provide a defined launch path without waiting for a final judgment.

Did the case involve biosimilar risk?

No. AbbVie v. Hetero was not a biosimilar case.

The dispute involved a small-molecule generic drug submitted through an ANDA under the Hatch-Waxman Act. The relevant regulatory issues were Paragraph IV certification, patent infringement, the 30-month stay, and ANDA approval. Biosimilar litigation under the Biologics Price Competition and Innovation Act was not implicated.

Issue	Applicability
ANDA	Yes
Paragraph IV certification	Yes
Hatch-Waxman litigation	Yes
BPCIA litigation	No
Biosimilar interchangeability	No
Reference product exclusivity for biologics	No

What was the Orange Book status of AndroGel 1.62%?

The FDA Orange Book listed patent information for AndroGel products, including Patent No. 6,503,894 during the period relevant to the Hetero action.[3] Orange Book listing created the statutory framework for Hetero’s Paragraph IV certification and AbbVie’s infringement suit.

Orange Book listing did not guarantee that the patent would survive litigation. A listed patent could be challenged for invalidity, noninfringement, or unenforceability. The listing also did not prevent FDA approval permanently. It generally supported a 30-month stay when the brand company filed a timely infringement action after receiving a Paragraph IV notice.

The regulatory position of any specific Hetero ANDA must be distinguished from the broader Orange Book status of AndroGel. FDA approval timing depends on the ANDA’s status, patent certifications, pediatric exclusivity, regulatory deficiencies, and any settlement-related license.

How strong was AbbVie’s patent estate?

AbbVie’s position was commercially meaningful but narrower than a broad composition-of-matter estate.

Strengths

The asserted patent addressed the testosterone gel product and its use. That type of claim can create a direct infringement risk when a generic applicant seeks approval for the same strength, dosage form, and labeled indication.

The patent had several practical advantages:

• It was listed in the Orange Book.
• It covered the branded product’s central delivery platform.
• A Paragraph IV certification created immediate litigation exposure.
• The lawsuit triggered the statutory approval stay.
• The patent remained in force during the core period of the litigation.

Limitations

The patent did not provide the same level of protection as a chemical composition-of-matter patent covering a new active ingredient. Testosterone was an established active ingredient. Generic applicants could attack the patent through invalidity, noninfringement, obviousness, written-description, enablement, and claim-construction defenses.

The estate also faced ordinary transdermal-product risks. A generic applicant could attempt to design around particular gel concentrations, excipients, permeation characteristics, dosing instructions, or manufacturing parameters. The practical scope of protection therefore depended on the claims asserted and the exact ANDA formulation.

What patent litigation affected generic AndroGel entry?

AbbVie litigated AndroGel-related patent disputes against multiple generic applicants. The Hetero case was one action in a broader generic-entry campaign involving testosterone gel products.

Competitive issue	Impact
Paragraph IV filings	Created early litigation against AbbVie
Listed formulation and method patents	Delayed approval while litigation or settlement remained active
Patent expiration	Reduced long-term blocking power
Generic formulation design	Created potential noninfringement routes
Multiple ANDA applicants	Increased pressure on settlement and launch timing
Product-specific patent listings	Made each ANDA’s risk profile different

The existence of parallel cases did not automatically determine Hetero’s outcome. Each defendant’s ANDA could contain different certifications, formulations, labeling proposals, and noninfringement arguments.

What generic launch scenarios existed after the case?

Three launch scenarios were commercially plausible.

Launch after patent expiration

Hetero could launch after expiration of the relevant listed patent and any applicable pediatric exclusivity or other statutory protection. This was the lowest litigation-risk path but delayed market entry until the end of the patent term.

Licensed launch

A settlement could provide Hetero with a defined entry date before or around patent expiration. The specific date and conditions are not established in the reported public record. A licensed launch would reduce uncertainty but could delay competition compared with a successful invalidity or noninfringement judgment.

At-risk launch

Hetero could launch before final resolution if it obtained approval and accepted the risk of an injunction, damages, or further litigation. There is no reported evidence that Hetero launched at risk under this case before the dispute ended.

What was the commercial exposure for AbbVie?

AndroGel was a material product for AbbVie’s predecessor business and later for AbbVie’s pharmaceutical portfolio. Generic entry threatened price erosion, volume loss, formulary displacement, and accelerated conversion to lower-cost testosterone products.

The specific revenue attributable to the Hetero defendant cannot be isolated from public case materials. The commercial exposure was affected by:

• the number of approved or pending generic testosterone gels;
• the strength and formulation covered by Hetero’s ANDA;
• the number of competing generic launches;
• payer substitution policies;
• the remaining term of the listed patents;
• the availability of other testosterone delivery systems.

A single generic launch would not necessarily create full market erosion. The financial impact would increase if multiple ANDA applicants launched simultaneously or if the first approved generic obtained substantial pharmacy substitution.

How does this case compare with a patent invalidity victory?

AbbVie v. Hetero produced less legal precedent than a litigated judgment.

Outcome type	Effect on AbbVie	Effect on Hetero	Precedential value
AbbVie wins at trial	Preserves blocking position	Delays or prevents launch	High
Hetero wins at trial	Weakens patent estate	Enables earlier launch	High
Settlement and dismissal	Preserves commercial flexibility	Provides negotiated certainty	Low
Case dismissed without public terms	Limits public visibility	Terms remain commercially confidential	Low

For investors and licensing teams, the case is best treated as a settlement-resolution event, not as evidence that the asserted patent was judicially validated.

What manufacturing and intellectual-property barriers applied?

Manufacturing barriers were secondary to the patent dispute but still relevant. A testosterone gel applicant had to demonstrate pharmaceutical equivalence, product quality, dosage uniformity, container compatibility, stability, and appropriate bioequivalence under FDA requirements.

Potential intellectual-property barriers included:

• gel composition claims;
• testosterone concentration claims;
• transdermal delivery claims;
• application and dosing methods;
• container or metering-pump technology;
• manufacturing-process claims;
• labeling that induced infringement.

A successful design-around could avoid one or more formulation claims, but the applicant still had to obtain FDA approval for the proposed product and labeling.

Key Takeaways

• AbbVie v. Hetero USA, No. 1:13-cv-00852, was a Hatch-Waxman case involving Hetero’s proposed generic AndroGel 1.62%.
• The principal patent associated with the action was U.S. Patent No. 6,503,894.
• Hetero’s Paragraph IV certification triggered AbbVie’s infringement suit and the statutory regulatory stay.
• The case ended without a reported trial, claim-construction decision, or merits judgment.
• Public materials do not establish the full settlement terms or a definitive Hetero launch date.
• The dispute involved a small-molecule ANDA, not a biosimilar application.
• The patent estate provided meaningful product protection but did not have the breadth of a new-chemical-entity composition patent.
• Generic-entry risk remained dependent on patent expiration, parallel ANDA litigation, formulation design, and any negotiated license.

FAQs

Was AbbVie v. Hetero a Humira biosimilar case?

No. It involved testosterone gel and an ANDA for a small-molecule generic product. Humira biosimilar litigation proceeded under a different statutory framework.

Which AbbVie product was challenged by Hetero?

Hetero challenged the AndroGel 1.62% testosterone gel product.

Did Hetero invalidate AbbVie’s AndroGel patent?

No reported decision in the case invalidated Patent No. 6,503,894. The case ended without a merits ruling.

Did the litigation establish that Hetero could launch before patent expiration?

No. The public record does not establish a definitive launch date or disclose all settlement conditions.

What is the principal patent number associated with the case?

U.S. Patent No. 6,503,894 was the principal patent associated with the litigation and AndroGel patent listings during the relevant period.

References

1. AbbVie Inc. v. Hetero USA Inc., No. 1:13-cv-00852, U.S. District Court for the District of Delaware (2013-2014), docket materials.
2. U.S. Patent No. 6,503,894, “Androgenic compositions and methods of use,” U.S. Patent and Trademark Office.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.